DE69535459D1 - Monoklonale antikörper spezifisch gegen vegf-rezeptoren und ihre verwendung - Google Patents
Monoklonale antikörper spezifisch gegen vegf-rezeptoren und ihre verwendungInfo
- Publication number
- DE69535459D1 DE69535459D1 DE69535459T DE69535459T DE69535459D1 DE 69535459 D1 DE69535459 D1 DE 69535459D1 DE 69535459 T DE69535459 T DE 69535459T DE 69535459 T DE69535459 T DE 69535459T DE 69535459 D1 DE69535459 D1 DE 69535459D1
- Authority
- DE
- Germany
- Prior art keywords
- monoclonal antibodies
- antibodies specific
- vegf receptors
- receptor
- vegf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US326552 | 1989-03-20 | ||
US19604194A | 1994-02-10 | 1994-02-10 | |
US196041 | 1994-02-10 | ||
US08/326,552 US5840301A (en) | 1994-02-10 | 1994-10-20 | Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors |
PCT/US1995/001678 WO1995021868A1 (en) | 1994-02-10 | 1995-02-10 | Monoclonal antibodies specific to vegf receptors and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69535459D1 true DE69535459D1 (de) | 2007-05-24 |
DE69535459T2 DE69535459T2 (de) | 2007-12-13 |
Family
ID=26891612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69535459T Expired - Lifetime DE69535459T2 (de) | 1994-02-10 | 1995-02-10 | Monoklonale antikörper spezifisch gegen vegf-rezeptoren und ihre verwendung |
Country Status (7)
Country | Link |
---|---|
US (2) | US5840301A (de) |
EP (2) | EP1602668A1 (de) |
AT (1) | ATE359090T1 (de) |
AU (1) | AU1914795A (de) |
CA (1) | CA2185683A1 (de) |
DE (1) | DE69535459T2 (de) |
WO (1) | WO1995021868A1 (de) |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6582959B2 (en) * | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
US20030206899A1 (en) * | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
US5367057A (en) * | 1991-04-02 | 1994-11-22 | The Trustees Of Princeton University | Tyrosine kinase receptor flk-2 and fragments thereof |
US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
US8211422B2 (en) * | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
US6872699B2 (en) | 1992-11-13 | 2005-03-29 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften, E.V. | Truncated Flk-1 receptor protein, methods of use and a recombinant vector containing a nucleotide encoding the truncated Flk-1 protein |
US6448077B1 (en) * | 1994-02-10 | 2002-09-10 | Imclone Systems, Inc. | Chimeric and humanized monoclonal antibodies specific to VEGF receptors |
US6811779B2 (en) | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
AUPM379394A0 (en) * | 1994-02-10 | 1994-03-03 | Ludwig Institute For Cancer Research | Immunointeractive molecules - i |
US20030108545A1 (en) * | 1994-02-10 | 2003-06-12 | Patricia Rockwell | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
US5861499A (en) | 1994-02-10 | 1999-01-19 | Imclone Systems Incorporated | Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain |
IL117645A (en) * | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
AU710696C (en) | 1995-09-08 | 2002-10-24 | Genentech Inc. | VEGF-related protein |
US6346398B1 (en) | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
US7034009B2 (en) | 1995-10-26 | 2006-04-25 | Sirna Therapeutics, Inc. | Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) |
US5942385A (en) * | 1996-03-21 | 1999-08-24 | Sugen, Inc. | Method for molecular diagnosis of tumor angiogenesis and metastasis |
AU2066797A (en) * | 1996-03-21 | 1997-10-10 | Sugen, Inc. | Assays for kdr/flk-1 receptor tyrosine kinase inhibitors |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
US6986890B1 (en) * | 1996-11-21 | 2006-01-17 | Kyowa Hakko Kogyo Co., Ltd. | Anti-human VEGF receptor Flt-1 monoclonal antibody |
ES2267136T3 (es) * | 1996-11-21 | 2007-03-01 | Kyowa Hakko Kogyo Kabushiki Kaisha | Anticuerpo monocional antirreceptor fit-1 del vegf humano. |
US6495579B1 (en) | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
EP3260468A1 (de) * | 1997-04-07 | 2017-12-27 | Genentech, Inc. | Anti-vegf-antikörper |
AU2469299A (en) * | 1998-01-23 | 1999-08-09 | Cornell Research Foundation Inc. | Purified populations of stem cells |
WO1999040118A1 (fr) * | 1998-02-04 | 1999-08-12 | Kyowa Hakko Kogyo Co., Ltd. | Anticorps diriges contre le recepteur kdr humain du vegf |
US20030224001A1 (en) * | 1998-03-19 | 2003-12-04 | Goldstein Neil I. | Antibody and antibody fragments for inhibiting the growth of tumors |
ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
AU2004200700B2 (en) * | 1998-05-20 | 2006-08-31 | Kyowa Hakko Kirin Co., Ltd. | Gene Recombinant Antibody |
JP3679406B2 (ja) * | 1998-05-20 | 2005-08-03 | 協和醗酵工業株式会社 | 遺伝子組換え抗体 |
US20030175271A1 (en) * | 1998-05-20 | 2003-09-18 | Kyowa Hakko Kogyo Co., Ltd. | VEGF activity inhibitor |
ATE428732T1 (de) * | 1998-05-20 | 2009-05-15 | Kyowa Hakko Kogyo Kk | Gen rekombinante antikörper |
AU3850299A (en) * | 1998-05-20 | 1999-12-06 | Kyowa Hakko Kogyo Co. Ltd. | Vegf activity inhibitors |
WO2000052470A1 (fr) * | 1999-03-04 | 2000-09-08 | Kyowa Hakko Kogyo Co., Ltd. | Moyen de diagnostic et de traitement de la leucemie |
WO2000064946A2 (en) | 1999-04-28 | 2000-11-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
BR0010524A (pt) * | 1999-05-14 | 2002-05-28 | Imclone Systems Inc | Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico |
ATE410685T1 (de) * | 1999-06-17 | 2008-10-15 | Kyowa Hakko Kogyo Kk | Diagnostikum und heilmittel für krankheiten unter teilnahme von makrozyten/makrophagen |
EP1267935A2 (de) * | 2000-01-12 | 2003-01-02 | Light Sciences Corporation | Behandlung von augenerkrankungen |
US7740841B1 (en) * | 2000-01-28 | 2010-06-22 | Sunnybrook Health Science Center | Therapeutic method for reducing angiogenesis |
CA2399022A1 (en) * | 2000-02-04 | 2001-08-09 | Supratek Pharma Inc. | Ligand for vascular endothelial growth factor receptor |
ATE406914T1 (de) * | 2000-02-10 | 2008-09-15 | Massachusetts Eye & Ear Infirm | Photodynamische therapie zur behandlung von augenerkrankungen |
EP1130032A1 (de) * | 2000-02-28 | 2001-09-05 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Einzelkette-Antikörper die den menschlichen vaskulären endothelialen Wachstumsfaktorrezeptor-2 (VEGFR-2/KDR) erkennen |
AU2001243418A1 (en) * | 2000-03-03 | 2001-09-17 | Imclone Systems Incorporated | Ve-cadherin and vegfr-2 antagonists for therapeutic modulation of angiogenesis |
JP2003529370A (ja) * | 2000-03-31 | 2003-10-07 | イムクローン システムズ インコーポレイティド | 血管浸透性に対する有害な作用を有さないve−カドヘリンに対する拮抗薬抗体 |
EP1299419A2 (de) * | 2000-05-24 | 2003-04-09 | Imclone Systems, Inc. | Bispezifische immunglobulinartige antigenbindende proteine und verfahren zur deren herstellung |
JP2004527456A (ja) * | 2000-08-09 | 2004-09-09 | イムクローン システムズ インコーポレイティド | Egf受容体拮抗剤による過増殖性の疾患の治療 |
EP1325121A2 (de) * | 2000-10-13 | 2003-07-09 | Institut de Cardiologie de Montreal | Antisense oligonukleotid gerichtet gegen gene von vegf rezeptoren von säugetieren und deren verwendungen |
US20080008704A1 (en) * | 2001-03-16 | 2008-01-10 | Mark Rubin | Methods of treating colorectal cancer with anti-epidermal growth factor antibodies |
JP4398644B2 (ja) | 2001-04-06 | 2010-01-13 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア | ErbB界面ペプチド擬態およびその使用方法 |
WO2002100326A2 (en) | 2001-05-01 | 2002-12-19 | The General Hospital Corporation | Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies |
IL159177A0 (en) | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
JP2005508298A (ja) * | 2001-06-20 | 2005-03-31 | イムクローン システムズ インコーポレイティド | アテローム性動脈硬化症及び他の炎症性疾患を処置する方法 |
WO2003002144A1 (en) * | 2001-06-26 | 2003-01-09 | Imclone Systems Incorporated | Bispecific antibodies that bind to vegf receptors |
CA2453474A1 (en) * | 2001-07-13 | 2003-01-23 | Imclone Systems Incorporated | Vegfr-1 antibodies to treat breast cancer |
JP2005526482A (ja) * | 2001-08-10 | 2005-09-08 | イムクローン システムズ インコーポレイティド | Vegfr−1を発現する幹細胞の単離および動員 |
FR2832154B1 (fr) * | 2001-11-09 | 2007-03-16 | Centre Nat Rech Scient | Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene |
CA2467836A1 (en) | 2001-11-20 | 2003-09-04 | Duke University | Interfacial biomaterials |
CN100457181C (zh) * | 2002-03-04 | 2009-02-04 | 伊姆克罗尼系统公司 | 用血管内皮生长因子受体拮抗剂抑制肿瘤生长的联合疗法 |
GB0206072D0 (en) * | 2002-03-15 | 2002-04-24 | Astrazeneca Ab | Epitope |
US7402397B2 (en) | 2002-05-21 | 2008-07-22 | Monogram Biosciences, Inc. | Detecting and profiling molecular complexes |
US20040229294A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB surface receptor complexes as biomarkers |
US20040229380A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB heterodimers as biomarkers |
US20050186204A1 (en) * | 2002-06-28 | 2005-08-25 | Peter Carmeliet | Use of antibodies against FLT-1 for the treatment of osteoporosis |
EP1622941A2 (de) * | 2003-03-20 | 2006-02-08 | ImClone Systems Incorporated | Methode zur produktion von anti-egfr antikörpern |
WO2008109433A2 (en) | 2007-03-02 | 2008-09-12 | The Cleveland Clinic Foundation | Anti-angiogenic peptides |
CN101966338A (zh) | 2003-06-09 | 2011-02-09 | 塞缪尔·瓦克萨尔 | 用胞外拮抗物和胞内拮抗物抑制受体酪氨酸激酶的方法 |
ES2388138T3 (es) | 2003-08-27 | 2012-10-09 | Ophthotech Corporation | Terapia de combinación para tratamiento de trastornos neovasculares oculares |
US7402399B2 (en) * | 2003-10-14 | 2008-07-22 | Monogram Biosciences, Inc. | Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy |
US20090155266A1 (en) * | 2004-01-16 | 2009-06-18 | Yale University | Methods and Compositions Relating to Vascular Endothelial Growth Factor and TH2 Mediated Inflammatory Diseases |
ES2387809T3 (es) * | 2004-03-19 | 2012-10-02 | Imclone Llc | Anticuerpo frente al receptor del factor de crecimiento epidérmico humano |
US20060234210A1 (en) * | 2004-04-14 | 2006-10-19 | Affinergy, Inc. | Filtration device and method for removing selected materials from biological fluids |
ES2523457T3 (es) | 2004-11-18 | 2014-11-26 | Imclone Llc | Anticuerpos contra el receptor 1 del factor de crecimiento endotelial vascular |
WO2007068895A1 (en) * | 2005-12-15 | 2007-06-21 | Astrazeneca Ab | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer |
US20070258976A1 (en) * | 2006-05-04 | 2007-11-08 | Ward Keith W | Combination Therapy for Diseases Involving Angiogenesis |
EP2125895B1 (de) * | 2007-02-02 | 2015-04-08 | Vegenics Pty Ltd | Vegf-rezeptorantagonisten zur behandlung von allommunität bei organtransplantationen und atherosklerose |
KR100883430B1 (ko) | 2007-06-13 | 2009-02-12 | 한국생명공학연구원 | 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도 |
JP5809415B2 (ja) | 2007-11-09 | 2015-11-10 | ペレグリン ファーマシューティカルズ,インコーポレーテッド | 抗vegf抗体の組成物および方法 |
US20120183547A1 (en) * | 2009-05-27 | 2012-07-19 | Mount Sinai School Of Medicine | Compositions and methods comprising vegfr-2 and vegfr-3 antagonists for the treatment of metastatic disease |
WO2011041093A1 (en) * | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
EP2538965B1 (de) | 2010-02-25 | 2017-04-12 | Schepens Eye Research Institute | Therapeutische zusammensetzungen zur behandlung des syndroms des trockenen auges |
US10274503B2 (en) | 2013-05-08 | 2019-04-30 | Vegenics Pty Limited | Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis |
KR20170132234A (ko) | 2015-03-30 | 2017-12-01 | 닛산 가가쿠 고교 가부시키 가이샤 | 혈관 내피 증식 인자 수용체에 결합하는 핵산 앱타머 |
CN106892980B (zh) * | 2017-01-25 | 2020-08-04 | 长春金赛药业有限责任公司 | 抗vegfr2单克隆抗体及其应用 |
US11723955B1 (en) | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
CA2083401C (en) * | 1991-02-22 | 2003-03-25 | Bruce I. Terman | Identification of a novel human receptor tyrosine kinase gene |
US5270458A (en) * | 1991-04-02 | 1993-12-14 | The Trustees Of Princeton University | Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2 |
US5185438A (en) * | 1991-04-02 | 1993-02-09 | The Trustees Of Princeton University | Nucleic acids encoding hencatoporetic stem cell receptor flk-2 |
JPH05244982A (ja) * | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
AU3236793A (en) * | 1991-12-12 | 1993-07-19 | Berlex Laboratories, Inc. | Recombinant and chimeric antibodies to c-erbB-2 |
AU4025193A (en) * | 1992-04-08 | 1993-11-18 | Cetus Oncology Corporation | Humanized C-erbB-2 specific antibodies |
CA2085291A1 (en) * | 1992-07-30 | 1994-01-31 | Martin L. Breitman | Novel receptor tyrosine kinase |
CA2145985C (en) * | 1992-10-28 | 2003-09-16 | Napoleone Ferrara | Vascular endothelial cell growth factor antagonists |
EP0669988B2 (de) * | 1992-10-29 | 2009-07-08 | The Australian National University | Angiogenese-inhibierende antikörper |
CN1173991C (zh) * | 1992-11-13 | 2004-11-03 | 马克斯普朗克科学促进协会 | 作为血管内皮生长因子受体的f1k-1 |
AUPM379394A0 (en) * | 1994-02-10 | 1994-03-03 | Ludwig Institute For Cancer Research | Immunointeractive molecules - i |
-
1994
- 1994-10-20 US US08/326,552 patent/US5840301A/en not_active Expired - Fee Related
-
1995
- 1995-02-10 EP EP05002398A patent/EP1602668A1/de not_active Withdrawn
- 1995-02-10 WO PCT/US1995/001678 patent/WO1995021868A1/en active IP Right Grant
- 1995-02-10 AT AT95911659T patent/ATE359090T1/de not_active IP Right Cessation
- 1995-02-10 DE DE69535459T patent/DE69535459T2/de not_active Expired - Lifetime
- 1995-02-10 AU AU19147/95A patent/AU1914795A/en not_active Abandoned
- 1995-02-10 CA CA002185683A patent/CA2185683A1/en not_active Abandoned
- 1995-02-10 EP EP95911659A patent/EP0741748B1/de not_active Expired - Lifetime
-
1997
- 1997-06-02 US US08/866,969 patent/US5874542A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO1995021868A1 (en) | 1995-08-17 |
DE69535459T2 (de) | 2007-12-13 |
EP0741748A1 (de) | 1996-11-13 |
AU1914795A (en) | 1995-08-29 |
ATE359090T1 (de) | 2007-05-15 |
EP1602668A1 (de) | 2005-12-07 |
EP0741748A4 (de) | 2000-07-05 |
CA2185683A1 (en) | 1995-08-17 |
US5840301A (en) | 1998-11-24 |
US5874542A (en) | 1999-02-23 |
EP0741748B1 (de) | 2007-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69535459D1 (de) | Monoklonale antikörper spezifisch gegen vegf-rezeptoren und ihre verwendung | |
NO991162L (no) | Monoklonale antistoffer mot det ekstracellulµre domene av humant VEGF-reseptorprotein (KDR) | |
DE69925730D1 (de) | 4-benzyl-piperidin-alkylsulfoxid-heterozyklen und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten | |
DE69617896T2 (de) | Humaner monoklonaler Antikörper gegen VEGF | |
DE69839270D1 (de) | Agonistische antikörper gegen den thrombopoietinrezeptor und deren therapeutische verwendungen | |
ATE470714T1 (de) | Antikörper gegen doppelintegrinen, zusammensetzungen, verfahren und verwendungen | |
DE69724428D1 (de) | Humanisierte antikörper die an das gleiche antigen wie antikörper nr-lu-13 binden und deren verwendung in "pretargeting" verfahren | |
NO955167L (no) | Monoklonalt anti-V-integrin-antistoff | |
DE69536078D1 (de) | Inhibitoren | |
EA199801043A1 (ru) | Антитела против домена ed-в в фибронектина, их конструирование и использование | |
DE69509765D1 (de) | N-heterocyclyl sulphonamid-derivate und ihre verwendung als endothelin-antagonisten | |
DE60015296D1 (de) | Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten | |
DE69837606D1 (de) | Cystein-reiche rezeptoren-train | |
DE60107221D1 (de) | Indolin-2-on derivate und deren verwendung als liganden der ocytocin rezeptoren | |
LV11630A (lv) | T sunu antigena receptora V apgabala pilna garuma olbaltumvielas | |
DE60114413D1 (de) | Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten | |
DE69435083D1 (de) | Antikörper gegen den IL-8 Rezeptor und deren therapeutische Verwendungen | |
SE9604731D0 (sv) | A component of intercellular junctions in the endothelium | |
IL139217A0 (en) | Monoclonal antibodies to the human ldl receptor, their production and use | |
DE69821988D1 (de) | Substituierte isochinoline derivate und ihre verwendung als anticonvulsiva | |
DE69028713T2 (de) | Schimäre immunoglobuline für cd4-rezeptoren | |
DE69024871D1 (de) | Monoklonaler Antikörper gegen menschliches BCDF und Immuntestverfahren unter dessen Verwendung | |
DE69129582D1 (de) | Antikörper gegen menschlichen plasmin-alpha 2-plasmininhibitor-komplex, hybridoma und immunoassay | |
DE69617010D1 (de) | Isazole derivate als fibrinogen-rezeptor-antagonisten | |
ATE290074T1 (de) | Monoklonaler antikörper gegen humanes mp52 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: IMCLONE LLC, DOVER, DEL., US |